Drugs / 4G7-CARD T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02893189 | Apr 2017 → Dec 2019 | B-cell neoplasm | University College, London | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4G7-CARD T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02893189 ↗ |
| Known as | CAR19 T-cells | “modified CAR19 T-cells (4G7-CARD T-cells)” NCT02893189 ↗ |
| Modality | Cell therapy | “modified CAR19 T-cells” NCT02893189 ↗ |
| Target | CD19 | “CD19 chimeric antigen receptor” PMID 40643148 ↗ Oct 2025 |